The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Stuart J Connolly, Lars Wallentin, Michael D Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A Reilly, Martina Brueckmann, Janice Pogue, Marco Alings, John V Amerena, Alvaro Avezum, Iris Baumgartner, Andrzej J Budaj, Jyh-Hong Chen, Antonio L Dans, Harald Darius, Giuseppe Di Pasquale, Jorge Ferreira, Greg C Flaker, Marcus D FlatherMaria Grazia Franzosi, Sergey P Golitsyn, David A Halon, Hein Heidbuchel, Stefan H Hohnloser, Kurt Huber, Petr Jansky, Gabriel Kamensky, Matyas Keltai, Sung Soon Kim, Chu-Pak Lau, Jean-Yves Le Heuzey, Basil S Lewis, Lisheng Liu, John Nanas, Razali Omar, Prem Pais, Knud E Pedersen, Leopoldo S Piegas, Dimitar Raev, Pal J Smith, Mario Talajic, Ru San Tan, Supachai Tanomsup, Lauri Toivonen, Dragos Vinereanu, Denis Xavier, Jun Zhu, Susan Q Wang, Christine O Duffy, Ellison Themeles, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

193 Citations (Scopus)


During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.
Original languageEnglish
Pages (from-to)237-243
Number of pages7
Issue number3
Publication statusPublished - 16 Jul 2013


  • Dose-Response Relationship, Drug
  • Humans
  • Stroke
  • Aged
  • Hemorrhage
  • beta-Alanine
  • Antithrombins
  • Benzimidazoles
  • Hospitalization
  • Aged, 80 and over
  • Embolism
  • Treatment Outcome
  • Middle Aged
  • Follow-Up Studies
  • Atrial Fibrillation
  • Female
  • Male

Cite this